Financial Support

If you’re having trouble paying for medications your doctor has prescribed for CF, there are resources available. Genentech now offers a co-pay card, help with insurance information, and the Genentech Access to Care Foundation, a program that may be available to help patients who are unable to pay for Pulmozyme. You may also be able to get help from the Additional CF Resources listed below.

Pulmozyme® Access Solutions® Co-Pay Card Program

Helping you stay connected through co-pay support

Pulmozyme Access Solutions offers Pulmozyme Access Solutions Co-Pay Card Program to help you with the out-of-pocket (OOP) costs of your Pulmozyme prescription. By enrolling in the Co-Pay Card Program, eligible patients can receive help with their monthly insurance co-payments.

Please contact us at 1-877-PZ4URCF (1-877-794-8723) (8:00AM - 8:00PM ET, Monday-Friday) if you have questions regarding the program. For more information about Pulmozyme, please visit: www.pulmozyme.com.

[Back to top]

Help with insurance

Pulmozyme Access Solutions

  • Works with you, your doctor and others to provide payment information

  • Checks on your health care plan's benefits and approvals

  • Gives information about which Pulmozyme supplier your health care plan wants you to use

  • Helps if you have concerns about your Pulmozyme co-pay

  • Can help find solutions if you have no heath care plan or your plan won't cover the costs of your Pulmozyme treatment

[Back to top]

Genentech Access to Care Foundation

The Genentech Access to Care Foundation (GATCF) helps patients who do not have insurance coverage for a Genentech medicine. Qualified patients enrolled in GATCF receive their medicine free of charge.

We are committed to helping you get our medicines regardless of your ability to pay. If you have no insurance, or your insurance plan denies you coverage for Pulmozyme, you can work with your doctor's office to apply to GATCF for free medicine.

[Back to top]

Additional CF Resources

Be sure to check the Resources and Links section of CF Living to find other websites that may provide you with more info.

[Back to top]

  • Join Now!
  • Share Your Story!
  • Financial Support

Indication and Usage

Daily administration of Pulmozyme® (dornase alfa) Inhalation Solution along with standard therapies is indicated in the management of cystic fibrosis patients to improve lung function. In patients with a forced vital capacity (volume of air exhaled with maximum effort and speed) greater than or equal to 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring the administration of injectable antibiotics. In our pivotal study, safety and efficacy of daily administration has not been studied in patients beyond 12 months.

Important Safety Information

  • Pulmozyme should not be used in patients who are allergic to any of its ingredients

  • Pulmozyme should be used along with standard therapies for cystic fibrosis

  • When starting Pulmozyme therapy, patients may experience change in or loss of their voice, discomfort in the throat, chest pain, red watery eyes, rash, dizziness, fever, or runny nose

  • These side effects are usually mild and short-lived

  • The effect of Pulmozyme on exercise tolerance has not been established in adults and children

For further information, please see the Pulmozyme full prescribing information. If you have questions, please discuss them with your CF healthcare team.

Kids & Tweens


Teens

Young Adults


Adults

Parents & Legal Guardians


Newly Diagnosed

Community Resources

Genentech: A Member of the Roche Group

This program is intended for U.S. residents only. © 2011 Genentech USA, Inc. All rights reserved.

Contact Us | Terms and Conditions | Privacy Policy | Site Map